Lonza to make cancer drug for Micromet

Swiss biopharmaceuticals group Lonza has agreed to manufacture Micromet's blinatumomab (MT103), a drug used to treat various haematologic cancers.

Swiss biopharmaceuticals group Lonza has agreed to manufacture Micromet's blinatumomab (MT103), a drug used to treat various haematologic cancers.

Micromet is a US biopharmaceutical company developing antibodies for the treatment of cancer, inflammation and autoimmune diseases.

Lonza says it will manufacture blinatumomab for clinical trials, develop the commercial scale process and supply the drug for the market if requested.

Blinatomumab has achieved the primary endpoint in a phase II clinical trial for the treatment of patients with acute lymphoblastic leukemia and has shown success in an ongoing phase I trial for the treatment of patients with non-Hodgkin's lymphoma.

Companies